The Alzheimer’s Tau Platform (ATP) is a Phase 2 clinical trial studying treatments that target tau and amyloid, two proteins that build up in the brain in Alzheimer’s disease. The study includes people with no noticeable memory problems or only very mild changes in memory and thinking.
Researchers are evaluating whether treatments that target tau, either alone or combined with an amyloid-targeting treatment, can reduce tau buildup and slow Alzheimer’s disease progression. They will also evaluate the treatments’ safety and tolerability.
The tau-targeting treatment being studied is AADvac1. Researchers will compare AADvac1 alone, AADvac1 combined with donanemab, and donanemab alone. Donanemab targets amyloid. Additional tau-targeting treatments may be added to the platform over time.
Who is eligible?
We are looking for people who:
- Are 50–80 years old. People ages 50–60 must have very mild changes in memory and thinking.
- Have no cognitive impairment or only very mild impairment, as determined by study testing.
- Have evidence of elevated amyloid and tau, as determined through screening blood tests and brain scans.
- Have a reliable study partner who can provide information about their health and daily functioning and participate in study visits.
- Are able and willing to complete study visits, testing, and treatment.
Additional eligibility criteria apply. The study team will review medical history, medications, and screening results to determine eligibility.
What is involved?
- Approximately 30 months of study treatment and assessments.
- Assignment by chance to one of three treatment groups: AADvac1 alone, AADvac1 plus donanemab, or donanemab alone.
- Blinded treatment, meaning participants and study teams do not know which treatment group a participant has been assigned.
- Regular memory and thinking tests, MRI and PET brain scans, blood tests, and safety assessments.
For more information, please contact the ATP Study Team:
Study Coordinator: Madina Karatanas
Phone: 206-685-8630
Email: madina03@uw.edu
Principal Investigator: Dr. Michael Rosenbloom
Study listing on ClinicalTrials.gov
Learn more about ATP from the Alzheimer’s Clinical Trials Consortium
